Navigation Links
NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil®
Date:6/5/2011

NKTR-102 for ovarian cancer patients, results from a subpopulation of patients from the Phase 2 clinical study of NKTR-102 in ovarian cancer patients, and the potential of certain other drug candidates in Nektar's pipeline.  These forward-looking statements involve substantial risks and uncertainties, including but not limited to one or more of the following: (i) NKTR-102 is in mid-stage clinical development and the risk of failure remains high and failure can unexpectedly occur at any stage for one or more of the cancer indications being studied (i.e. ovarian cancer, breast cancer, and colorectal cancer) due to efficacy, safety or other unpredictable factors even after earlier clinical results have been positive; (ii) the data package required and the timing for regulatory approval of a new drug application (NDA) is very uncertain and difficult to predict due to broad regulatory discretion, changing standards of care, available approved therapies, the size of the completed clinical trials and the statistical significance of the results, the potential need for comparative clinical studies against approved therapies, and other important factors that are not within the control of Nektar; (iii) the results from the expanded Phase 2 clinical study for NKTR-102 in platinum-resistant/refractory ovarian cancer patients are unlikely to result in a review or an approval of an NDA by the United States Food and Drug Administration; (iv) the timing or success of the commencement or end of clinical trials and commercial launch of new drugs may be delayed or unsuccessful due to commercial and funding considerations, regulatory delays, clinical trial design, slower than anticipated patient enrollment, drug manufacturing challenges, changing standards of care, clinical outcomes, or delay or failure in obtaining regulatory approval in one or more important markets; (v) the Phase 2 results for NKTR-102 in ovarian cancer patients previously treated with PLD set forth in this pre
'/>"/>
SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting
2. Nektar Announces New Phase 2 Data for NKTR-102 to Be Presented at 2011 ASCO Annual Meeting
3. FDA Grants Orphan Drug Designation for Nektars Investigational Drug, NKTR-102, for Treatment of Women with Ovarian Cancer
4. NKTR-102 Demonstrates Significant Efficacy as Single-Agent in Second- or Third-Line Treatment in Metastatic Breast Cancer Patients
5. NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress
6. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
7. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
8. Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings
9. Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting
10. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
11. NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... , Dec. 17, 2014  Beamz Interactive, ... interactive music products, today announced that it has ... leading manufacturer and supplier of innovative prosthetic, orthotic ... As part of the agreement, RSL Steeper will ... solution specifically configured for use within UK residential ...
(Date:12/17/2014)... and RALEIGH, N.C. ... Marketing Communications, LLC (CTMC), and Integrated Clinical Trial ... recruitment and retention for clinical trials announce that ... Clinical Trial Marketing Services (i-CTMS). i-CTMS will provide ... services to pharmaceutical, biotechnology and medical device companies. ...
(Date:12/15/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/32cmct/inferior_vena ) has ... (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 Global Inferior Vena Cava ... by 2016. The North America ... while Europe claims approximately 27% ...
Breaking Medicine Technology:Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 3Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 2Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 3Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 2Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 3Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 4
... Grifols, a global healthcare company and biopharmaceutical manufacturer based ... an Expert Advisory Council in Transfusion Medicine drawing on ... across the globe.  The role of the Expert Advisory ... Grifols, own transfusion medicine research and development activities. ...
... CareFusion Corporation (NYSE: CFN ... of Carlos M. Nunez, M.D. as its chief medical officer ... and hospitalist as well as an experienced health care technology ... the areas of clinical effectiveness, information technology, public policy and ...
Cached Medicine Technology:Grifols Establishes Expert Advisory Council in Transfusion Medicine 2Grifols Establishes Expert Advisory Council in Transfusion Medicine 3CareFusion Appoints Carlos M. Nunez, M.D. as Chief Medical Officer 2
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... HealthDay Reporter , MONDAY, Sept. 19 (HealthDay News) -- ... all types of dementia, including Alzheimer,s disease, finds a new ... The study of more than 1,000 people in Japan found ... to 20 percent of people with normal blood sugar levels. ...
... with low sunlight are up to 3 times more ... should take high levels of Vitamin D supplements, according to ... "This study shows that the current one-size fits ... don,t work," said Adam Murphy, M.D., a clinical instructor in ...
... improvements in treating heart attack patients needing emergency artery-opening ... hospitals that can perform the procedure, according to a ... Association . Fast response is critical for ST-segment ... is caused by a complete blockage of blood supply ...
... (MEMPHIS, Tenn. September 19, 2011) The largest study ever ... the tumors carried extra copies of specific genes linked to ... Research Hospital investigators. The findings identify possible new ... as diffuse intrinsic pontine glioma (DIPG). Current survival rates for ...
... of boredom or fatigue, yawning might also be a ... by Andrew Gallup, a postdoctoral research associate in Princeton ... first involving humans to show that yawning frequency varies ... to yawn when the heat outdoors exceeds body temperature. ...
... MONDAY, Sept. 19 (HealthDay News) -- Obese 8- and ... their normal-weight peers, a new study finds. In the ... height and weight, at ages 4 and 5 and then ... questionnaires that assessed children,s mental health and health-related quality of ...
Cached Medicine News:Health News:More Evidence Links Diabetes, Dementia 2Health News:More Evidence Links Diabetes, Dementia 3Health News:One size doesn't fit all for vitamin D and men 2Health News:Emergency treatment for heart attack improving but delays still occur 2Health News:Emergency treatment for heart attack improving but delays still occur 3Health News:Key regulatory genes often amplified in aggressive childhood tumor of the brainstem 2Health News:Key regulatory genes often amplified in aggressive childhood tumor of the brainstem 3Health News:More than a sign of sleepiness, yawning may cool the brain 2Health News:More than a sign of sleepiness, yawning may cool the brain 3Health News:Obese Kids May Face Social, Emotional Woes 2Health News:Obese Kids May Face Social, Emotional Woes 3
Lyphochek Whole Blood Metals Control contains the major heavy metals of toxicological and environmental importance for whole blood analysis....
Lyphochek Whole Blood Control is a unique product designed to monitor immunosuppressants, red cell folate and lead in whole blood assays. This control has three critical levels for each analyte and i...
qUAntify Plus Control is a combination urine dipstick and microscopic control. The control is available in either 12 mL centrifuge tubes or 120 mL flip-top squeeze bottles....
Lyphochek Maternal Serum Control is a trilevel product with analytes at clinically significant levels to monitor maternal serum analysis....
Medicine Products: